| Budget Amount *help |
¥16,250,000 (Direct Cost: ¥12,500,000、Indirect Cost: ¥3,750,000)
Fiscal Year 2016: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2015: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2014: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
|
|---|
| Outline of Final Research Achievements |
Mycobacterium bovis Bacillus Calmette-Guerin (BCG) vaccine confers incomplete protection against tuberculosis because it is not effective for inducing long-term immunity. Therefore, it is urgently required to develop improved vaccines. We found that IL-7 and IL-21 are pleiotropic common cytokines that affect IL-17+γδT cells and CD8+T cells, respectively. Based on these results, we examined the effects of recombinant BCG secreting fusion protein Ag85B/IL-7, or IL-21 (rBCG-Ag85B-IL7, rBCG-Ag85B-IL21) on cell-mediated immune responses against BCG. The levels of effector CD8+ T cells were significantly higher butexhausted CD8+ T cells were lower after immunization with rBCG-Ag85B-IL21 compared with rBCG-Ag85B. The levels of IL-17+γδ T cells and CD4+ Th1 cells were higher in rBCG-Ag85B-IL7-immunized mice than rBCG-Ag85B-immunized mice. rBCG-Ag85B-IL-7 or IL-21 vaccination capable of inducing long-term efficient immunity might be used as an effective vaccine for tuberculosis.
|
